# Maternal Angiotensin Increases Placental Leptin in Early Gestation via an Alternative Renin-Angiotensin System Pathway: Suggesting a Link to Preeclampsia

- **DOI:** [10.1161/hypertensionaha.120.16425](https://doi.org/10.1161/hypertensionaha.120.16425)
- **Rating:** Sound (3.1 out of 5)
- **Verdict:** Placental receptor mapping and paired peptide measurements advance pregnancy RAS biology, but the proposed Ang IV–LNPEP–leptin mechanism remains untested at its decisive links.
- **Framework version:** v5.13
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-11-13
- **Evaluation page:** https://www.nabu.science/paper/10.1161%2Fhypertensionaha.120.16425

## Key claims

1. Ang IV decreases trophoblastic mitochondrial respiration and increases placental leptin via placental LNPEP.
   - Support: Tentative
   - Type: Primary finding
   - Basis: Ang IV-induced leptin and LNPEP dependence were not directly tested
   - Location: Abstract
2. serum Ang III (mean±SEM, 2.6±0.6 pmol/L) and Ang IV (mean±SEM, 4.6±1.0 pmol/L), the 2 peptide hormones resulting from Ang I and Ang II, were significantly increased in pregnancy
   - Support: Supported
   - Type: Secondary
   - Basis: paired equilibrium measurements support increases in 10 ART patients without isolating pregnancy from treatment-associated changes
   - Location: Results, Serum Ang IV Increases in Pregnancy, Figure 2E
3. Lower placental LNPEP in preeclampsia and in first-trimester patients at high-risk for preeclampsia suggests a new alternative route in maternal RAS signaling and may contribute to hypertension and disease in pregnancy.
   - Support: Tentative
   - Type: Secondary
   - Basis: observational group differences with gestational-age confounding and risk classification do not establish a contribution to disease
   - Location: Abstract; Fig. 5
4. Leptin downregulates placental LNPEP.
   - Support: Tentative
   - Type: Secondary
   - Basis: small first-trimester explant experiments with conflicting treatment doses limit the unqualified claim
   - Location: Novelty and Significance, What Is New
5. The cell cluster annotated as syncytiotrophoblast expressed LNPEP as the only Ang receptor, whereas AGTR1 was exclusively expressed in cells annotated as fibroblasts.
   - Support: Supported
   - Type: Secondary
   - Basis: single-cell expression patterns are corroborated by spatial localization methods
   - Location: Results, Maternal and Fetal Angs Have Different Target Placental RAS Receptors, Figure 1

## Strengths

- **Complementary methods resolve placental receptor localization** Single-cell expression analysis, in situ padlock probes, and immunofluorescence distinguish syncytiotrophoblast LNPEP from AGTR1 around fetal vessels, addressing conflicting earlier localization reports.
  - Dimension: contribution
  - Location: Results, Figure 1; Discussion, opening paragraph
- **Paired sampling tracks early pregnancy peptides** Mass spectrometry compares Ang I–IV within the same 10 women before conception and around week 7, showing increased Ang III and Ang IV in the studied ART cohort.
  - Dimension: methodological rigour
  - Location: Methods, Serum Ang Measurement; Results, Figure 2E
- **Clinical associations receive explicit confounder checking** Reduced LNPEP is reported in two independently recruited preeclampsia cohorts and an early high-risk group. The Discussion explicitly investigates labor and preterm-delivery effects using an independent single-cell dataset.
  - Dimension: positioning
  - Location: Results, Figure 5A–B; Discussion, gestational-age analysis

## Limitations

- **Headline pathway exceeds direct experimental tests** The abstract attributes leptin induction to Ang IV acting through LNPEP, but Figure 4 measures induction after Ang II and does not directly manipulate LNPEP. The complete pathway therefore remains a hypothesis rather than an identified mechanism.
  - Dimension: methodological rigour
  - Location: Abstract; Results, Figures 3–4
- **Metabolic assays omit independent replicate definitions** Figure 3 reports metabolic effects and statistical tests without specifying sample sizes or whether replication represents independent experiments or wells. Explant reporting also leaves donor-versus-tissue replication unclear.
  - Dimension: methodological rigour
  - Location: Methods, Seahorse XF Experiments and Placental Explants; Figures 3–4 legends
- **Treatment concentrations and cohort counts conflict** Methods and Figure 4 disagree on candesartan dosing, 0.1 versus 1 μmol/L, and leptin dosing, 100 versus 10 ng/mL. The high-risk groups total 17 in the abstract versus 16 in Figure 5B, and preeclampsia cohort counts also vary across sections.
  - Dimension: reporting
  - Location: Abstract; Methods, Sample Collection and Placental Explants; Discussion; Figures 4–5 legends

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted
  - Ang IV decreases trophoblastic mitochondrial respiration and increases placental leptin via placental LNPEP: "Candesartan was used in its active form (Selleckchem, Munich, Germany) at a concentration of 0.1 μmol/L" (Methods, Placental Explants) vs "AT1R (Ang II receptor type 1)-blocker candesartan (1 μmol/L)" (Figure 4C legend). The stated candesartan concentrations differ tenfold between Methods and Figure 4C. → Effect on result unclear
  - Leptin downregulates placental LNPEP: "Leptin at a concentration of 100 ng/mL (Gibco)" (Methods, Placental Explants, leptin concentration) vs "Ang II (0.1 μmol/L), Ang IV (4 nmol/L), and leptin (10 ng/mL) for 6 h" (Figure 4 legend, panel E). The stated leptin concentrations differ tenfold between Methods and Figure 4E. → Effect on result unclear
  - Lower placental LNPEP in preeclampsia and in first-trimester patients at high-risk for preeclampsia suggests a new alternative route in maternal RAS signaling and may contribute to hypertension and disease in pregnancy: "from early-onset preeclamptic (n=54) and age-matched controls (n=29)" (Abstract, cohort sizes) vs "Preeclamptic placentae and respective controls were sampled at the University Hospital of Graz, Austria (n=42) and within an independent cohort15 at the Oslo University Hospital, Norway (n=33)." (Methods, Sample Collection). The abstract gives 54+29=83 samples, whereas the Methods give 42+33=75 across Graz and Oslo. → Effect on result unclear
  - Lower placental LNPEP in preeclampsia and in first-trimester patients at high-risk for preeclampsia suggests a new alternative route in maternal RAS signaling and may contribute to hypertension and disease in pregnancy: "Graz cohort: 253.8±4.1 days (n=27) controls and 236.9±3.5 days (n=37) preeclamptic pregnancies" (Discussion, gestational age paragraph) vs "Preeclamptic placentae and respective controls were sampled at the University Hospital of Graz, Austria (n=42)" (Methods, Sample Collection). The Discussion's Graz groups sum to 27+37=64, whereas Methods reports Graz n=42. → Effect on result unclear
  - Lower placental LNPEP in preeclampsia and in first-trimester patients at high-risk for preeclampsia suggests a new alternative route in maternal RAS signaling and may contribute to hypertension and disease in pregnancy: "(high-risk for preeclampsia, n=9) and controls (n=8)" (Abstract, high-risk cohort) vs "indicating high-risk for PE (n=16; Mann-Whitney U test, P<0.05)" (Figure 5 legend, panel B). The abstract's groups sum to 9+8=17, whereas Figure 5B reports n=16. → Effect on result unclear
- **Reporting and transparency:** Clean. Written consent and local ethics approval are declared, disclosures state none, and data are available upon reasonable request. No retained finding establishes a reporting or transparency concern about research conduct.
  - Conflict of interest: declared · Ethics approval: declared · Data availability: declared
- **Reference integrity:** Clean
  - 62 references in manuscript
  - 61 of 61 checkable references found in an index
  - 1 are books, websites or datasets — counted, but not index-checkable
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-11-13
